CSL Shares Fall to New Multi-Year Low After 50% Drop

CSL shares (ASX:CSL) struck a fresh multi-year low at A$125.78, capping a 49.91% decline over twelve months as repeated guidance cuts and margin pressures continue to erode confidence in what was once Australia’s most valuable healthcare stock.

The CSL share price closed at their lowest level in nearly 10 years, extending a relentless stair-step decline that has wiped approximately A$60 billion from CSL’s market cap over the past year. A look at the 1 year chart below and you will see clearly that the shares have suffered three particularly severe drops, in August, October, and February, each triggered by strategic setbacks or earnings disappointments that have fundamentally altered the market’s view of the company’s growth trajectory.

Trading volumes have remained elevated throughout the decline, suggesting broad-based repositioning rather than panic selling.

What Has Been Driving CSL Shares?

August: Margin Reset Shatters Bull Thesis

The first major break occurred on 19 August 2025, when CSL’s full-year 2025 results delivered a strategic bombshell that would prove the catalyst for months of selling pressure. Management abandoned its long-standing guidance that CSL Behring’s plasma gross margins would recover to pre-COVID levels of approximately 57% within three to five years, a core assumption underpinning the bull case for the stock.

The company simultaneously announced a sweeping restructure including up to 15% workforce reductions (approximately 3,000 positions), plasma centre closures, and plans to demerge its Seqirus influenza vaccine division as a separately listed entity by 2026. The Seqirus business had delivered negative 9% revenue growth in FY25, even with support from one-off avian flu contracts that would not repeat.

Shares plunged as much as 19% in a single session, one of CSL’s worst trading days on record. The market had effectively priced CSL as a steady compounder with visible margin recovery; instead, it now faced a complex multi-year restructure with elevated execution risk.

Despite the turmoil, CSL’s core franchises continued to grow, with Behring posting 6% revenue growth and the recently acquired Vifor renal business expanding 14%. Management framed the restructure as necessary to defend margins in a structurally changed plasma collection environment, where donor acquisition costs and competitive dynamics had permanently shifted.

October Downgrade Deepens Crisis

Just as markets began to digest the August reset, CSL delivered another blow at its October annual general meeting. The company cut FY26 profit guidance, reducing underlying net profit after tax and amortisation growth expectations to 4–7% from the previously guided 7–10% range at constant currency.

More troubling, Seqirus FY26 revenue was now expected to decline in the mid-teens percentage range, versus earlier guidance for a high single-digit decline. Weak flu vaccination rates and margin pressure across the vaccine portfolio had accelerated faster than management anticipated.

The shares fell approximately 14% on the day of the revised guidance, extending a prior 16% decline and marking CSL’s second-worst single-day fall after the August move. Analyst commentary highlighted an “information void” around the drivers of weaker medium-term growth, with several brokerages questioning the credibility of management’s forecasting after two major resets in as many quarters.

The Seqirus demerger timeline also began to slip during this period, with management acknowledging that volatility in the US flu vaccine market would likely push the spin-off beyond the original June 2026 target date.

In an attempt to signal confidence and provide price support, CSL announced an on-market buyback programme of up to A$750 million, running from 4 September 2025 through 30 June 2026. While bulls interpreted the buyback as management backing its own stock at depressed levels, the programme proved too modest to offset the scale of institutional selling.

Markets questioned the capital allocation logic of deploying cash into buybacks while simultaneously cutting guidance, deferring growth investments, and delaying the Seqirus spin-off. The buyback became emblematic of a broader tension: CSL continued to reinvest approximately one-third of cash earnings into the business, yet was now guiding for only low single-digit revenue growth and mid single-digit profit growth.

February Results Confirm Margin Compression

CSL’s half-year 2026 results, released on 11 February, provided little relief for beleaguered shareholders. Trailing twelve-month revenue reached US$15.4 billion with basic earnings per share of US$2.89, but analysis focused squarely on ongoing net margin compression relative to historic levels.

Higher plasma collection costs, weaker Seqirus margins, and integration expenses from the Vifor acquisition offset top-line growth. Management maintained FY26 guidance for revenue growth of approximately 2–3% and NPATA growth of 4–7%, figures that retail shareholders increasingly viewed as inadequate given the company’s substantial reinvestment rate and historically premium valuation.

The shares fell a further 5% in the session following the results, dropping to around A$171 and extending what analysts described as a brutal multi-year rout. Concerns emerged that Seqirus manufacturing inefficiencies could drag on guidance again, while Behring’s new immunoglobulin products faced reimbursement hurdles in key European markets.

Social media and investment forums reflected the frustration of long-term holders, many of whom had accumulated positions above A$250 and were now sitting on losses exceeding 40%. Discussions questioned whether CSL’s low dividend yield (currently below 1.5%) and modest growth profile justified continued ownership compared with broad market index exposure.

Structural Questions Replace Cyclical Optimism

What began as concerns over temporary COVID-related disruptions to plasma collection has evolved into a fundamental reassessment of CSL’s competitive position and margin structure. The plasma therapeutics industry has seen persistent donor cost inflation, increased competition for collection, and pricing pressure from payers seeking to control healthcare expenditure.

Behring’s immunoglobulin franchise remains the crown jewel, with structural demand drivers from an ageing population and growing diagnosis rates for immune deficiencies. However, the pathway back to pre-COVID margins now appears multi-year at best, requiring both operational excellence in collection efficiency and favourable pricing dynamics that remain uncertain.

The delayed Seqirus spin-off continues to weigh on sentiment, with markets viewing the vaccine business as more cyclical and volatile than previously understood. Flu vaccination rates in the United States have trended lower, while the competitive landscape has intensified with new entrants and technology platforms challenging CSL’s manufacturing-based moat.

Vifor, acquired in 2022 for US$11.7 billion, has delivered solid growth in iron deficiency and nephrology treatments, but integration costs have been higher than initially modelled. Bulls argue the market is ascribing minimal value to Vifor and Seqirus, effectively valuing CSL as Behring alone, a scenario that could present upside if the restructure succeeds and segment clarity improves post-demerger.

Analyst Community Divided on Path Forward

Sell-side analysts remain split on CSL’s prospects, with target prices ranging from A$150 to A$240 depending on assumptions around margin recovery timing and the success of the restructure. Consensus estimates have been steadily revised lower throughout the past year, with FY27 and FY28 forecasts now incorporating more conservative margin trajectories and growth rates.

Bears emphasise that CSL is simply re-rating to a valuation multiple appropriate for mid single-digit earnings growth, arguing the stock deserved to trade at a premium only when it delivered high single-digit to low double-digit compound growth with visible margin expansion. That thesis has been comprehensively dismantled by the past twelve months of results and guidance resets.

Bulls counter that the market has over-extrapolated near-term challenges, pointing to CSL’s entrenched competitive positions, substantial R&D pipeline, and US$1.5 billion US expansion plan for Behring plasma collection capacity. They argue that once the restructure is complete and Seqirus is spun out, CSL will emerge with cleaner segment profiles and more focused capital allocation, potentially reopening room for a valuation re-rating.

Several brokerages have adopted a “wait and see” stance, acknowledging that while valuation appears compelling on traditional metrics, the lack of near-term catalysts and ongoing execution uncertainty makes the risk-reward profile unattractive until greater clarity emerges on margin trends and the demerger timeline.

What Comes Next for CSL

The company faces a critical twelve-month period as it executes the workforce reduction, completes the Behring and Vifor commercial integration, and navigates the complex Seqirus separation process. Management has emphasised that cost-cutting initiatives will deliver approximately A$500 million in annual savings once fully implemented, providing some offset to margin pressures.

Key milestones for markets to monitor include quarterly plasma collection volume trends, pricing dynamics in the US immunoglobulin market, progress on new product launches including Behring’s next-generation therapies, and concrete timing for the Seqirus demerger. Any further guidance resets would likely trigger another leg lower in the share price, while evidence of stabilising margins could provide the foundation for a sustained recovery.

The broader healthcare sector backdrop remains supportive, with demographic tailwinds and innovation in biologics underpinning long-term demand growth. However, CSL must demonstrate it can translate that structural opportunity into improving financial returns, something it has failed to do convincingly over the past year.

For now, CSL shares remain trapped in a downtrend driven by repeated disappointments and eroding confidence in management’s strategic narrative. Bulls who have awaited support at each successive level have been consistently disappointed, and today’s fresh low suggests that process is not yet complete. Whether CSL can stabilise and rebuild credibility, or faces further derating as it transitions from growth compounder to mature large-cap, will define the investment case for Australia’s once-dominant healthcare champion.